Adverse Drug Reactions Associated with CYP 2B6 Polymorphisms in HIV/AIDS-Treated Patients in Yaoundé, Cameroon.

Carine Nguefeu NkenfouBarbara Atogho TiedeuCeline Nguefeu NkenfouAkindeh M NjiJean Paul ChedjouCalvino Tah FombohCharles KouanfackWilfred F Mbacham

Published in: The application of clinical genetics (2019)

These findings demonstrate that ADRs among HIV/AIDS patients under ART may be associated with the genetic variability of the metabolizing enzyme CYP 2B6. Genotyping for this gene may guide the better administration of Efavirenz and Nevirapine to Cameroonian patients.

Keyphrases

hiv aids
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
antiretroviral therapy
peritoneal dialysis
adverse drug
genome wide
emergency department
hiv infected
dna methylation
copy number
genome wide identification